ARTH

Arch Therapeutics, Inc. [ARTH] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ARTH Stock Summary

In the News

ARTH Financial details

Company Rating
-
Market Cap
7.16M
Income
-7.98M
Revenue
115.33K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
20 May 2024
P/E
-0.93
Forward P/E
-
PEG
1.32
P/S
672.87
P/B
-0.87
P/C
-
P/FCF
-6.66
Quick Ratio
0.01
Current Ratio
0.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.31
EPS next Y
-
EPS next Q
-
EPS this Y
-36.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
16.07%
EPS Q/Q
9.62%
-
-
-
-
SMA20
-4.35%
SMA50
22.22%
SMA100
-37.14%
Inst Own
-
Inst Trans
-
ROA
-479%
ROE
123%
ROC
0.64%
Gross Margin
-46%
Oper. Margin
-13652%
Profit Margin
-19850%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.39-18.0
52W High
-
52W Low
-
RSI
41.52
Rel Volume
0.02
Avg Volume
4.98K
Volume
100
Perf Week
-16.99%
Perf Month
-13.73%
Perf Quarter
-49.8%
Perf Half Y
-61.6%
-
-
-
-
Beta
3.563
-
-
Volatility
0.01%, 0.02%
Prev Close
-10.7%
Price
0.192
Change
-10.7%

Something similar

Top by Market Cap
FXAIX
BRH.DE
ABEA.DE
AAPL
AMZN
Same Sector
ADXN.SW
AMED
SRZNW
0LO3.L
BUDZ
Same Price Range
GNPX
9998.HK
ACARIX.ST
OMQS
1843.HK
Similar Market Cap
CRZY
SHVLF
JNHA.DE
IPPP
TANN.L

Company Profile

Healthcare Biotechnology
  • Volume Average 4.98K
  • Market Capitalization 7.16M
  • Employee 8
  • CEO Dr. Terrence W. Norchi M.D.
  • Headquarters Framingham,MA,US
  • IPO Date 2013-01-02
  • Website https://www.archtherapeutics.com

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.